RHHBY vs. NVS
RHHBY (Roche Holding AG) and NVS (Novartis AG) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, RHHBY returned 7.66%/yr vs 10.33%/yr for NVS. A 0.53 correlation means they provide meaningful diversification when combined.
Performance
RHHBY vs. NVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RHHBY achieves a 1.04% return, which is significantly lower than NVS's 9.43% return. Over the past 10 years, RHHBY has underperformed NVS with an annualized return of 7.66%, while NVS has yielded a comparatively higher 10.33% annualized return.
RHHBY
- 1D
- -1.81%
- 1M
- -1.06%
- YTD
- 1.04%
- 6M
- 6.55%
- 1Y
- 27.52%
- 3Y*
- 12.73%
- 5Y*
- 4.71%
- 10Y*
- 7.66%
NVS
- 1D
- -1.84%
- 1M
- 0.27%
- YTD
- 9.43%
- 6M
- 15.91%
- 1Y
- 27.84%
- 3Y*
- 17.18%
- 5Y*
- 13.87%
- 10Y*
- 10.33%
RHHBY vs. NVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RHHBY Roche Holding AG | 1.04% | 52.86% | 0.23% | -4.02% | -22.21% | 20.20% | 9.94% | 33.47% | 2.16% | 14.32% |
NVS Novartis AG | 9.43% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
Correlation
The correlation between RHHBY and NVS is 0.64, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.64 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.56 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.56 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.58 |
Correlation (All Time) Calculated using the full available price history since Jan 3, 2001 | 0.53 |
The correlation between RHHBY and NVS shifts across timeframes, from 0.53 (all time) to 0.64 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
RHHBY:
$5.42
NVS:
$6.99
RHHBY:
9.33
NVS:
20.95
RHHBY:
1.51
NVS:
5.06
RHHBY:
$107.65B
NVS:
$56.05B
RHHBY:
$79.28B
NVS:
$42.19B
RHHBY:
$31.01B
NVS:
$22.40B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RHHBY vs. NVS — Risk / Return Rank
RHHBY
NVS
RHHBY vs. NVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Roche Holding AG (RHHBY) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RHHBY | NVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.35 | ||
| Sortino ratioReturn per unit of downside risk | -0.28 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.24 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 1.43 | 2.21 | -0.78 |
| Martin ratioReturn relative to average drawdown | 3.49 | 5.43 | -1.94 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RHHBY | NVS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.01 | 1.36 | -0.35 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.20 | 0.74 | -0.54 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | 0.53 | -0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.42 | -0.07 |
Drawdowns
RHHBY vs. NVS - Drawdown Comparison
The maximum RHHBY drawdown since its inception was -45.73%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for RHHBY and NVS.
Loading charts...
Drawdown Indicators
| RHHBY | NVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.73% | -42.10% | -3.63% |
Max Drawdown (1Y)Largest decline over 1 year | -19.38% | -12.65% | -6.73% |
Max Drawdown (3Y)Largest decline over 3 years | -23.46% | -19.95% | -3.51% |
Max Drawdown (5Y)Largest decline over 5 years | -40.88% | -20.42% | -20.46% |
Max Drawdown (10Y)Largest decline over 10 years | -40.88% | -26.03% | -14.85% |
Current DrawdownCurrent decline from peak | -13.99% | -10.52% | -3.47% |
Average DrawdownAverage peak-to-trough decline | -12.84% | -10.93% | -1.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.91% | 5.14% | +2.77% |
Volatility
RHHBY vs. NVS - Volatility Comparison
Roche Holding AG (RHHBY) has a higher volatility of 8.10% compared to Novartis AG (NVS) at 6.16%. This indicates that RHHBY's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RHHBY | NVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.10% | 6.16% | +1.94% |
Volatility (6M)Calculated over the trailing 6-month period | 18.55% | 14.45% | +4.10% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.48% | 20.63% | +6.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.39% | 18.85% | +4.54% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.58% | 19.62% | +2.96% |
Dividends
RHHBY vs. NVS - Dividend Comparison
RHHBY's dividend yield for the trailing twelve months is around 3.07%, less than NVS's 3.26% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVS Novartis AG | 3.26% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
RHHBY Roche Holding AG | 3.07% | 2.69% | 3.87% | 3.55% | 3.23% | 1.57% | 1.66% | 1.70% | 3.58% | 3.25% | 3.57% | 2.91% |
Financials
RHHBY vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between Roche Holding AG and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RHHBY vs. NVS - Profitability Comparison
RHHBY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Roche Holding AG reported a gross profit of 21.75B and revenue of 30.32B. Therefore, the gross margin over that period was 71.7%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
RHHBY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Roche Holding AG reported an operating income of 7.05B and revenue of 30.32B, resulting in an operating margin of 23.2%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
RHHBY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Roche Holding AG reported a net income of 5.42B and revenue of 30.32B, resulting in a net margin of 17.9%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
Frequently Asked Questions
RHHBY and NVS have a correlation of 0.64, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RHHBY has higher volatility (8.10%) compared to NVS (6.16%). In terms of maximum drawdown, RHHBY dropped -45.73% vs NVS's -42.10%.
NVS currently has the higher Sharpe Ratio (1.36 vs 1.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RHHBY and NVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer